资讯

The American Journal of Managed Care2 小时
RemeGen’s Telitacicept Gains China Approval for Myasthenia Gravis
Telitacicept is a dual-targeting agent that attaches to and blocks the effects of 2 key signaling proteins, B-lymphocyte ...